RESUMEN
Intra-articular tumours are uncommonly encountered in routine practice and may present diagnostic challenges to pathologists. Challenges unique to this site include distinction from more common reactive synovial conditions, which are far more common; histologic variability; superimposed reactive changes; and often, lack of provided clinicoradiological context. This article reviews the pathology of the synovial tumours and tumour-like lesions, including diagnostic pearls, pitfalls and rare entities.
Asunto(s)
Membrana Sinovial , Humanos , Diagnóstico Diferencial , Membrana Sinovial/patología , Membrana Sinovial/diagnóstico por imagen , Artropatías/diagnóstico por imagen , Artropatías/patología , Patología Quirúrgica/métodosRESUMEN
AIMS: Amplification of the murine double minute-2 (MDM2) gene, which is usually detected with fluorescence in-situ hybridisation (FISH), is the key driving event for atypical lipomatous tumours (ALTs)/well-differentiated liposarcomas (WDLs). We sought to determine the concordance between the histopathological findings and MDM2 FISH in the diagnosis of ALT/WDL, and to identify the histological features of MDM2-amplified tumours lacking classic atypia. METHODS AND RESULTS: We performed a retrospective analysis of all mature lipomatous lesions subjected to MDM2 FISH analysis at our institution. MDM2 FISH analysis was performed on 439 mature lipomatous lesions: 364 (82.9%) were negative and 75 (17%) were positive. In 17 of 75 (22.6%) ALTs/WDLs, cytological atypia was not identified on initial histological assessment, thus favouring lipoma. On review, these cases shared common histological features, consisting of a very low number of relatively small stromal cells within the tumour lobules, with mildly coarse chromatin and oval nuclei, admixed with unremarkable adipocytes in a tumour background devoid of fibroconnective septa, areas of fibrosis, or blood vessels. These cells matched the cells in which FISH showed MDM2 amplification. In contrast, 13 cases (3.5%) regarded as suspicious for ALT/WDL on the basis of histology lacked MDM2 amplification and were reclassified following the FISH findings. CONCLUSIONS: We conclude that a subset of lipoma-like ALTs/WDLs are not associated with any of the features typically described in ALT/WDL. Our study also showed that tumours >100 mm are more likely to be ALT/WDL; however, a history of recurrence or concerning clinical/radiological features was not significantly associated with classification as ALT/WDL.
Asunto(s)
Lipoma/metabolismo , Liposarcoma/metabolismo , Proteínas Proto-Oncogénicas c-mdm2/metabolismo , Neoplasias de los Tejidos Blandos/metabolismo , Adulto , Anciano , Humanos , Hibridación Fluorescente in Situ , Lipoma/genética , Lipoma/patología , Liposarcoma/genética , Liposarcoma/patología , Persona de Mediana Edad , Proteínas Proto-Oncogénicas c-mdm2/genética , Estudios Retrospectivos , Neoplasias de los Tejidos Blandos/genética , Neoplasias de los Tejidos Blandos/patologíaRESUMEN
Breast tumors with lipomatous or liposarcomatous components are infrequently encountered, but can be a source of diagnostic difficulty if the context of the fatty differentiation is not recognized. Among the true adipocytic tumors, lipoma is the most common lipomatous tumor arising in the breast. Several mammary spindle cell tumors may show adipocytic differentiation, including fibroepithelial tumors and myofibroblastoma. Liposarcomatous components most often arise in malignant phyllodes tumors, as opposed to primary liposarcomas of the breast which are believed to be uncommon. This article will review the spectrum fat-containing tumors of the breast with an emphasis on differential diagnosis and insights from recent molecular studies.
Asunto(s)
Adipocitos/patología , Angiolipoma/patología , Neoplasias de la Mama/patología , Lipoma/patología , Liposarcoma/patología , Neoplasias Fibroepiteliales/patología , Angiolipoma/genética , Angiolipoma/terapia , Biomarcadores de Tumor/genética , Biopsia , Neoplasias de la Mama/genética , Neoplasias de la Mama/terapia , Diferenciación Celular , Diagnóstico Diferencial , Femenino , Predisposición Genética a la Enfermedad , Humanos , Lipoma/genética , Lipoma/terapia , Liposarcoma/genética , Liposarcoma/terapia , Técnicas de Diagnóstico Molecular , Neoplasias Fibroepiteliales/genética , Neoplasias Fibroepiteliales/terapia , Fenotipo , Valor Predictivo de las Pruebas , PronósticoRESUMEN
Sarcomatoid melanoma is a rare type of melanoma lacking typical histologic features of melanoma and often lacks expression of S100 protein and melanocyte-specific markers. Given the rarity of this entity, its clinicopathologic findings are not well defined. We report 2 cases of sarcomatoid melanoma received in consultation: a 65-year-old woman with a right breast mass and a 62-year-old man with a left plantar heel mass. Both lesions were ulcerated, pedunculated, highly cellular proliferations of atypical spindle cells arranged as fascicles and/or sheets. The tumor cells of the breast mass expressed CD10 and vimentin diffusely but S100 protein only focally. The tumor cells of the heel mass lacked expression of melanocytic markers altogether, except for weak, very focal S100 protein expression. At the junctional edge of the breast mass and in the ulcer base of the heel mass, focal precursor melanoma was present and exhibited melanocytic differentiation. We report these cases to emphasize the importance of meticulous histologic inspection at the lesion's edge and/or ulcer base to correctly identify the conventional precursor melanoma in these rare lesions to ensure appropriate diagnosis and subsequent clinical management as treatment options may be significantly different from those offered for sarcomas.
Asunto(s)
Melanoma/diagnóstico , Melanoma/patología , Neoplasias Cutáneas/diagnóstico , Neoplasias Cutáneas/patología , Anciano , Femenino , Humanos , Masculino , Persona de Mediana EdadRESUMEN
BACKGROUND: Clear cell sarcoma typically arises in deep soft tissues of the foot/ankle. Primary head and neck clear cell sarcoma is rare. We report three molecularly confirmed primary head and neck clear cell sarcoma and review the literature. METHODS: Head and neck clear cell sarcoma with no primary elsewhere were retrieved from archival/consultation files. English language literature review of all reported head and neck clear cell sarcoma was performed. RESULTS: Three cases were identified. The tumors, all in men, presented on the scalp of a 33-year-old, face of a 20-year-old and tongue of a 44-year-old. Tumors ranged from 0.6 to 1.4 cm. All had typical features of clear cell sarcoma, including nests of tumor cells divided by fibrous septae. One had multinucleated wreath-like giant cells. One had a focal junctional component. Immunohistochemistry was positive for S100 (three out of three), HMB45 (three out of three) and Melan-A (two out of three). All had EWSR1 rearrangements by fluorescence in situ hybridization. Follow up available for one patient revealed no evidence of disease after wide excision and radiation. Seven additional reported cases were identified and tabulated. CONCLUSION: Head and neck clear cell sarcoma is rare but should be considered in the differential diagnosis of nested tumors with fibrous septae. Molecular analysis should be considered for definitive diagnosis regardless of location.
Asunto(s)
Neoplasias Faciales/patología , Sarcoma de Células Claras/patología , Neoplasias Cutáneas/patología , Neoplasias de la Lengua/patología , Adulto , Humanos , MasculinoRESUMEN
Angiomatoid fibrous histiocytoma (AFH) is a soft tissue tumour of intermediate (rarely metastasising) malignant potential, which harbours EWSR1/FUS gene fusions. These tumours can express anaplastic lymphoma kinase (ALK) in the absence of gene rearrangement or copy number alteration and can also coexpresses Pan-TRK immunohistochemistry (IHC). All EWSR1/FUS-rearranged AFH were retrieved from the files of three institutions and Pan-TRK (EPR17341), ALK and BRAF V600E IHC were performed. Fourteen AFH cases were identified, which included three cases of intracranial mesenchymal tumours with FET-CREB fusions. PanTRK and ALK positive immunostaining was identified in 9 (64.2%) and 12 (85.7%) cases, respectively. No NTRK or ALK translocations or increased copy number/amplification were identified in all eight cases which had fluorescence in situ hybridisation and/or next generation sequencing for NTRK1-3 and ALK available for assessment. None of the cases expressed BRAF-V600E.Although our study is limited, our report is the first to document PanTRK expression in AFH in the absence of identifiable NTRK1-3 gene alterations.
Asunto(s)
Neoplasias Encefálicas , Histiocitoma Fibroso Benigno , Histiocitoma Fibroso Maligno , Humanos , Histiocitoma Fibroso Benigno/genética , Proteínas Proto-Oncogénicas B-raf/genética , Histiocitoma Fibroso Maligno/genética , Histiocitoma Fibroso Maligno/patología , Neoplasias Encefálicas/patología , Reordenamiento Génico , Proteínas Tirosina Quinasas Receptoras/genéticaRESUMEN
Molecular techniques are increasingly important in the practice of surgical pathology. In soft tissue tumors, there are a number of tumors with recurring cytogenetic abnormalities. Knowledge of these abnormalities has furthered our understanding of these tumors and has also allowed development of molecular techniques to aid in the diagnosis. This review will focus on mesenchymal tumors with specific cytogenetic abnormalities that may present as a superficial tumor of the dermis or subcutis.
Asunto(s)
Mesodermo/patología , Técnicas de Diagnóstico Molecular/métodos , Neoplasias Cutáneas/diagnóstico , Neoplasias de los Tejidos Blandos/diagnóstico , Biomarcadores de Tumor/metabolismo , Neoplasias Óseas/diagnóstico , Neoplasias Óseas/genética , Neoplasias Óseas/metabolismo , Aberraciones Cromosómicas , ADN de Neoplasias/análisis , Dermatofibrosarcoma/diagnóstico , Dermatofibrosarcoma/genética , Dermatofibrosarcoma/metabolismo , Fascitis/diagnóstico , Fascitis/genética , Fascitis/metabolismo , Fibrosarcoma/diagnóstico , Fibrosarcoma/genética , Fibrosarcoma/metabolismo , Hemangioendotelioma Epitelioide/diagnóstico , Hemangioendotelioma Epitelioide/genética , Hemangioendotelioma Epitelioide/metabolismo , Hemangiosarcoma/diagnóstico , Hemangiosarcoma/etiología , Hemangiosarcoma/genética , Histiocitoma Fibroso Maligno/diagnóstico , Histiocitoma Fibroso Maligno/genética , Histiocitoma Fibroso Maligno/metabolismo , Humanos , Hibridación Fluorescente in Situ , Neoplasias Inducidas por Radiación/diagnóstico , Neoplasias Inducidas por Radiación/etiología , Neoplasias Inducidas por Radiación/genética , Proteínas de Fusión Oncogénica/genética , Sarcoma de Células Claras/diagnóstico , Sarcoma de Células Claras/genética , Sarcoma de Células Claras/metabolismo , Sarcoma de Ewing/diagnóstico , Sarcoma de Ewing/genética , Sarcoma de Ewing/metabolismo , Neoplasias Cutáneas/genética , Neoplasias Cutáneas/metabolismo , Neoplasias de los Tejidos Blandos/genética , Neoplasias de los Tejidos Blandos/metabolismo , Translocación GenéticaRESUMEN
Cellular myofibromas/myopericytomas harboring recurring SRF fusions are recently characterized as rare and diagnostically challenging entities, which can mimic myogenic sarcomas. These tumors belong to the pericytic/perivascular myoid tumor family, which comprises a group of genetically heterogenous and sometimes morphologically overlapping entities. In this series, we describe 3 cases of SRF-rearranged cellular myofibromas/perivascular myoid tumors with a smooth muscle-like phenotype in children. The children ranged from 7 to 16 years of age, and all presented with a painless mass in the extremities, 2 of which were deep-seated. Histologically, the tumors demonstrated a smooth muscle-like morphology and immunophenotype with mild atypia and low-level mitotic activity. Prominent dense collagen deposition and coarse calcification was observed in 2 tumors. RNA sequencing revealed SRF fusions in all cases, with each tumor showing a different 3' partner gene, RELA, NFKBIE, and NCOA3. Of these, NCOA3 has not been reported previously, and this expands the molecular spectrum by identifying a novel fusion partner for SRF. Given that histological features can be worrisome for a myogenic sarcoma, wider awareness of this emerging tumor is valuable to avoid potential misclassification.
Asunto(s)
Miofibroma , Sarcoma , Neoplasias de los Tejidos Blandos , Humanos , Extremidades , Miofibroma/genética , Recurrencia Local de Neoplasia , Sarcoma/genética , Neoplasias de los Tejidos Blandos/genéticaRESUMEN
Our aim was to utilise a 241-gene RNA hybridisation capture sequencing (CaptureSeq) gene panel to identify unexpected fusions in undifferentiated, unclassified or partly classified sarcomas of young individuals (<40 years). The purpose was to determine the utility and yield of a large, targeted fusion panel as a tool for classifying tumours that do not fit typical diagnostic entities at the time of the original diagnosis. RNA hybridisation capture sequencing was performed on 21 archival resection specimens. Successful sequencing was obtained in 12 of 21 samples (57%), two of which (16.6%) harboured translocations. A novel NEAT1::GLI1 fusion, not previously reported in the literature, presented in a young patient with a tumour in the retroperitoneum, which displayed low grade epithelioid cells. The second case, a localised lung metastasis in a young male, demonstrated a EWSR1::NFATC2 translocation. No targeted fusions were identified in the remaining 83.4% (n=10) of cases. Forty-three per cent of the samples failed sequencing as a result of RNA degradation. RNA-based sequencing is an important tool, which helps to redefine the classification of unclassified or partly classified sarcomas of young adults by identifying pathogenic gene fusions in up to 16.6% of the cases. Unfortunately, 43% of the samples underwent significant RNA degradation, falling below the sequencing threshold. As CaptureSeq is not yet available in routine pathology practice, increasing awareness of the yield, failure rate and possible aetiological factors for RNA degradation is fundamental to maximise laboratory procedures to improve RNA integrity, allowing the potential identification of significant gene alterations in solid tumours.
Asunto(s)
Sarcoma , Neoplasias de los Tejidos Blandos , Adulto Joven , Humanos , Masculino , Sarcoma/diagnóstico , Sarcoma/genética , Sarcoma/patología , Fusión Génica , Factores de Transcripción/genética , Neoplasias de los Tejidos Blandos/diagnóstico , Neoplasias de los Tejidos Blandos/genética , Neoplasias de los Tejidos Blandos/patología , Reordenamiento Génico , Proteínas de Fusión Oncogénica/genéticaRESUMEN
In this study we used the Illumina Infinium Methylation array to investigate in a cohort of matched archival human tissue samples (n = 32) from 14 individuals with soft tissue sarcomas if genome-wide methylation changes occur during metastatic and recurrent (Met/Rec) disease. A range of sarcoma types were selected for this study: leiomyosarcoma (LMS), myxofibrosarcoma (MFS), rhabdomyosarcoma (RMS) and synovial sarcoma (SS). We identified differential methylation in all Met/Rec matched samples, demonstrating that epigenomic differences develop during the clonal evolution of sarcomas. Differentially methylated regions and genes were detected, not been previously implicated in sarcoma progression, including at PTPRN2 and DAXX in LMS, WT1-AS and TNXB in SS, VENTX and NTRK3 in pleomorphic RMS and MEST and the C14MC / miR-379/miR-656 in MFS. Our overall findings indicate the presence of objective epigenetic differences across primary and Met/Rec human tissue samples not previously reported.
Asunto(s)
Biomarcadores de Tumor/genética , Metilación de ADN , Epigénesis Genética , Regulación Neoplásica de la Expresión Génica , Metástasis de la Neoplasia/patología , Recurrencia Local de Neoplasia/patología , Sarcoma/patología , Adulto , Anciano , Femenino , Perfilación de la Expresión Génica , Humanos , Masculino , Persona de Mediana Edad , Metástasis de la Neoplasia/genética , Recurrencia Local de Neoplasia/genética , Pronóstico , Sarcoma/genéticaRESUMEN
We assessed the frequency of programmed death-ligand 1 (PD-L1) expression by immunohistochemistry (IHC) in a cohort of 522 sarcomas from 457 patients, incuding a subset of 46 patients with 63 matched samples from local recurrence or metastases with primary tumours and/or metachronous metastases. We also investigated the correlation of PD-L1 with the presence and degree of tumour-infiltrating lymphocytes (TILs) in a subset of cases. IHC was performed using the PD-L1 SP263 companion kit (VENTANA) on tissue microarrays from an archival cohort. Evaluation of PD-L1 and TILs was performed on full sections for a subset of 23 cases. Fisher's exact and Mann Whitney test were used to establish significance (P <0.05). PD-L1 positive expression (≥1%) was identified in 31% of undifferentiated pleomorphic sarcomas, 29% of angiosarcomas, 26% of rhabdomyosarcomas, 18% of myxofibrosarcomas, 11% of leiomyosarcomas and 10% of dedifferentiated liposarcomas. Negative expression was present in all atypical lipomatous tumous/well-differentiated lipoasarcomas, myxoid liposarcomas, synovial sarcomas, pleomorphic liposarcomas, and Ewing sarcomas. PD-L1 IHC was concordant in 81% (38 of 47) of matched/paired samples. PD-L1 IHC was discordant in 19% (9 of 47 matched/paired samples), displaying differences in the proportion of cells expressing PD-L1 amongst paired samples with the percentage of PD-L1-positive cells increasing in the metastatic/recurrent site compared to the primary in 6 of 9 cases (67%). Significant correlation between PD-L1 expression and the degree of TILs was exclusively identified in the general cohort of leiomyosarcomas, but not in other sarcoma subtypes or in metastatic/recurrent samples. We conclude that the prevalence of PD-L1 expression in selected sarcomas is variable and likely to be clone dependent. Importantly, we demonstrated that PD-L1 can objectively increase in a small proportion of metastases/recurrent sarcomas, offering the potential of treatment benefit to immune checkpoint inhibitors in this metastatic setting.
Asunto(s)
Antígeno B7-H1/análisis , Sarcoma/patología , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Masculino , Persona de Mediana Edad , Metástasis de la Neoplasia/patología , Recurrencia Local de Neoplasia/patología , PrevalenciaRESUMEN
We recently encountered a case of primary pulmonary angiomatoid fibrous histiocytoma (AFH), which was initially misdiagnosed as inflammatory myofibroblastic tumor (IMT) based in part on anaplastic lymphoma kinase (ALK) expression by immunohistochemistry (IHC). Prompted by this experience, we evaluated ALK expression in 11 AFH, 15 IMT, and 11 follicular dendritic cell sarcomas using 3 different antibody clones: D5F3, 5A4, and ALK1. ALK IHC positive cases were analyzed with fluorescence in situ hybridization (FISH) using dual color ALK break-apart probe kit. The majority of AFH cases studied were positive for ALK IHC with at least 1 antibody (9/11 D5F3, 6/9 5A4, 1/9 ALK1), most demonstrating moderate to strong cytoplasmic staining. AFH with positive ALK IHC showed no ALK gene rearrangement by FISH (0/8) with ALK copy number ranging from 1.6 to 2.1. Sixty-seven percent of IMT were ALK positive by IHC (10/15 D5F3, 8/15 5A4, 7/15 ALK1), and 9 of the 10 cases were positive for ALK gene rearrangement by FISH. All follicular dendritic cell sarcomas were negative for ALK by IHC (D5F3 and 5A4). Our results indicate that ALK expression in AFH is common, particularly with the highly sensitive D5F3 and 5A4 antibodies and enhanced detection systems, and may be a potential source of diagnostic confusion with IMT. The underlying mechanism of ALK expression in AFH is unclear, although it does not appear to be from ALK rearrangement or amplification.
Asunto(s)
Quinasa de Linfoma Anaplásico/biosíntesis , Biomarcadores de Tumor/análisis , Histiocitoma Fibroso Maligno/diagnóstico , Miofibroma/diagnóstico , Quinasa de Linfoma Anaplásico/análisis , Quinasa de Linfoma Anaplásico/genética , Diagnóstico Diferencial , Reordenamiento Génico , Histiocitoma Fibroso Maligno/genética , Humanos , Neoplasias Pulmonares/diagnóstico , Neoplasias Pulmonares/genética , Miofibroma/genéticaRESUMEN
OBJECTIVES: Desmoplastic small round cell tumor (DSRCT) is an aggressive round cell sarcoma that arises in the abdominal cavity/pelvis of young males. We sought to expand its clinicopathologic spectrum. METHODS: Cases of DSRCT presenting in patients >30 years of age or tumors arising outside of the abdominal cavity/pelvis were retrieved. RESULTS: Thirty-four cases were identified. Sixteen tumors arose at atypical sites (head/neck, intracranial, thigh, axilla/shoulder, inguinal/paratesticular, intraosseous, and uterine corpus). The remaining 18 patients were older than 30 years, and their tumors involved the abdomen or pelvis. The majority of cases showed areas with classic histology, while 6 cases exhibited solid growth and 5 showed macronodular architecture. Cytologic appearance included round cell, rhabdoid, epithelioid, and small cell. CONCLUSION: DSRCT may arise at nonabdominal locations in both pediatric and adult populations, as well as intra-abdominally in older adults, and these tumors exhibit high rates of metastasis and morbidity.
Asunto(s)
Tumor Desmoplásico de Células Pequeñas Redondas/patología , Adolescente , Adulto , Niño , Preescolar , Estudios de Cohortes , Tumor Desmoplásico de Células Pequeñas Redondas/genética , Femenino , Humanos , Masculino , Persona de Mediana Edad , Proteínas de Fusión Oncogénica/genética , Proteína EWS de Unión a ARN/genética , Factores Sexuales , Proteínas WT1/genética , Adulto JovenRESUMEN
Mesenchymal tumours of the breast comprise a broad spectrum of entities that frequently pose diagnostic challenges to surgical pathologists. Metaplastic carcinoma and phyllodes tumour are site-specific mimics that account for the majority of tumours in the breast with a sarcomatoid appearance. Although uncommon, mammary tumours with fibroblastic, adipocytic or vascular differentiation may be encountered, spanning the spectrum from benign to malignant. Tumours with histiocytoid morphology are potential traps due to bland cytomorphology and resemblance to reactive processes. This comprehensive review provides a diagnostic approach to specific challenging mesenchymal tumours of the breast and their mimics, with a discussion on the salient morphological, immunohistochemical and molecular features that allow accurate diagnosis and will help the pathologist avoid potential pitfalls.
Asunto(s)
Neoplasias de la Mama/diagnóstico , Mesenquimoma/diagnóstico , Neoplasias de la Mama/patología , Diagnóstico Diferencial , Femenino , Humanos , Mesenquimoma/patologíaRESUMEN
Recurrent NAB2-STAT6 gene fusions have recently been identified in solitary fibrous tumour by next generation sequencing. Our aim was to examine the sensitivity and specificity of STAT6 immunohistochemistry for solitary fibrous tumour versus other morphologically similar soft tissue tumours. STAT6 expression was evaluated in 54 solitary fibrous tumours of various sites and 99 soft tissue tumours in the histological differential diagnosis. We used a rabbit monoclonal STAT6 antibody (1:100), which has not been reported by others, on formalin fixed, paraffin embedded whole sections and tissue microarray slides. Only nuclear staining of STAT6 was considered positive. Distribution of staining was scored as: 0 (no staining), 1+ (1-25%), 2+ (26-50%), 3+ (>50%). Intensity was scored as weak, moderate or strong. Nuclear STAT6 staining was present in all SFT cases tested (54/54, sensitivity 100%), regardless of histology, anatomical site or CD34 status. The majority of cases showed 3+ and strong staining. All tested cases of cellular angiofibroma (0/9), myofibroblastoma (0/10), spindle cell lipoma (0/10), benign fibrous histiocytoma (0/13), dermatofibrosarcoma protruberans (0/9), low-grade fibromyxoid sarcoma (0/7), schwannoma (0/8), desmoid-type fibromatosis (0/8), monophasic synovial sarcoma (0/11), malignant peripheral nerve sheath tumour (0/7), and mesenchymal chondrosarcoma (0/7) were negative for STAT6 (specificity 100%). Our study further supports the utility of STAT6 immunohistochemistry as an adjunct in the diagnosis of solitary fibrous tumour.
Asunto(s)
Anticuerpos Monoclonales , Biomarcadores de Tumor/análisis , Diagnóstico Diferencial , Factor de Transcripción STAT6/biosíntesis , Neoplasias de los Tejidos Blandos/diagnóstico , Tumores Fibrosos Solitarios/diagnóstico , Adulto , Anciano , Anciano de 80 o más Años , Animales , Femenino , Humanos , Inmunohistoquímica , Masculino , Persona de Mediana Edad , Conejos , Sensibilidad y Especificidad , Análisis de Matrices TisularesRESUMEN
A number of soft tissue tumors are characterized by recurring genetic abnormalities. The identification of these abnormalities has advanced our understanding of the biology of these tumors and has led to the development of molecular tests that are helpful diagnostically. This review will focus on the application of molecular diagnostic testing in select mesenchymal tumors of the dermis and subcutis.
Asunto(s)
Neoplasias Cutáneas/genética , Neoplasias de los Tejidos Blandos/genética , Dermatofibrosarcoma/genética , Dermatofibrosarcoma/patología , Hemangioendotelioma Epitelioide/genética , Hemangioendotelioma Epitelioide/patología , Hemangiosarcoma/genética , Hemangiosarcoma/patología , Histiocitoma Fibroso Maligno/genética , Histiocitoma Fibroso Maligno/patología , Humanos , Neoplasias Inducidas por Radiación/genética , Neoplasias Inducidas por Radiación/patología , Sarcoma/genética , Sarcoma/patología , Sarcoma de Células Claras/genética , Sarcoma de Células Claras/patología , Sarcoma de Ewing/genética , Sarcoma de Ewing/patología , Neoplasias Cutáneas/patología , Neoplasias de los Tejidos Blandos/patologíaRESUMEN
Diagnostics in the field of breast carcinoma are constantly evolving. The recent wave of molecular methodologies, both microscope and non-microscope based, have opened new ways to gain insight into this disease process and have moved clinical diagnostics closer to a 'personalized medicine' approach. In this review we highlight some of the advancements that laboratory medicine technology is making toward guiding the diagnosis, prognosis, and therapy selection for patients affected by breast carcinoma. The content of the article is largely structured by methodology, with a distinct emphasis on both microscope based and non-microscope based diagnostic formats. Where possible, we have attempted to emphasize the potential benefits as well as limitations to each of these technologies. Successful molecular diagnostics, applied in concert within the morphologic context of a patient's tumor, are what will lay the foundation for personalized therapy and allow a more sophisticated approach to clinical trial stratification. The future of breast cancer diagnostics looks challenging, but it is also a field of great opportunity. Never before have there been such a plethora of new tools available for disease investigation or candidate therapy selection.